Asset Details
Do you wish to reserve the book?
Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
Do you wish to request the book?
Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas
2008
Overview
This study identifies the genetic fingerprint of poorly differentiated endometrioid endometrial carcinomas (G3-EEC) and analyses the potential utility of trefoil factor 3 (TFF3) as novel serum marker in G3-EEC. Affymetrix microarrays were used to identify the gene expression patterns of 19 snap-frozen G3-EEC and 15 normal endometrium (NE) biopsies. Quantitative real-time PCR (qRT-PCR) and immunohistochemistry were used to validate TFF3 expression. Finally, TFF3 serum levels were determined by ELISA in 25 G3-EEC patients, 42 healthy controls, and in 13 endometrial hyperplasia patients. Hierarchical cluster analysis showed TFF3 as the top differentially expressed gene between 363 upregulated genes in G3-EEC, when compared with NE. Trefoil factor 3 gene expression levels analysed by qRT-PCR significantly correlated with Affymetrix results (
P
<0.001; rs=0.85). By immunohistochemistry, TFF3 protein was significatively more expressed in EEC compared with NE (
P
<0.01), with cytoplasmatic positivity in 79% G3-EEC and 18% NE. Patients harbouring G3-EECs had significantly higher TFF3 serum concentration by ELISA when compared with healthy patients (
P
<0.001) or patients harbouring endometrial hyperplasia (
P
=0.012). In conclusion, TFF3 is highly expressed at gene and protein level in G3-EEC. Further investigations on a wider set of samples are warranted to validate TFF3 as a novel serum marker for early detection and/or monitoring of G3-EEC patients.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
Biological and medical sciences
/ Biomarkers, Tumor - genetics
/ Biomedical and Life Sciences
/ Endometrial Neoplasms - blood
/ Endometrial Neoplasms - diagnosis
/ Endometrial Neoplasms - genetics
/ Enzyme-Linked Immunosorbent Assay
/ Female
/ Gynecology. Andrology. Obstetrics
/ Humans
/ Oncology
/ Proteins
/ Tumors
